E
Acurx Pharmaceuticals, Inc.
ACXP
$0.33
-$0.029-8.08%
E
Sell
3/19/2024Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 3/19/2024 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 100.52% from -$2.09M to -$4.2M, EBIT declined 64.19% from -$3.12M to -$5.11M, and earnings per share declined from -$0.2395 to -$0.3695.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 3/19/2024 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 100.52% from -$2.09M to -$4.2M, EBIT declined 64.19% from -$3.12M to -$5.11M, and earnings per share declined from -$0.2395 to -$0.3695.
D
Sell
12/6/2023Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 12/6/2023 due to an increase in the total return index and volatility index.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 12/6/2023 due to an increase in the total return index and volatility index.
E
Sell
11/15/2023Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.03 to 2.19.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.03 to 2.19.
D
Sell
11/1/2023Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 11/1/2023 due to an increase in the volatility index, growth index and solvency index. Operating cash flow increased 18.43% from -$1.93M to -$1.58M.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 11/1/2023 due to an increase in the volatility index, growth index and solvency index. Operating cash flow increased 18.43% from -$1.93M to -$1.58M.
E
Sell
3/14/2023Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 3/14/2023 due to a decline in the valuation index.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/28/2023Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to D- from D on 2/28/2023 due to a decline in the volatility index and total return index.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to D- from D on 2/28/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and valuation index.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and valuation index.
E
Sell
2/8/2023Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D from D- on 2/3/2023 due to an increase in the growth index, total return index and volatility index.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D from D- on 2/3/2023 due to an increase in the growth index, total return index and volatility index.
D
Sell
8/24/2022Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 8/24/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 1.86% from -$2.67M to -$2.62M, and earnings per share increased from -$0.2609 to -$0.26.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 8/24/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 1.86% from -$2.67M to -$2.62M, and earnings per share increased from -$0.2609 to -$0.26.
E
Sell
5/23/2022Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 5/23/2022 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 25.05% from -$1.5M to -$1.88M, EBIT declined 1.64% from -$2.63M to -$2.67M, and earnings per share declined from -$0.2581 to -$0.2609.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 5/23/2022 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 25.05% from -$1.5M to -$1.88M, EBIT declined 1.64% from -$2.63M to -$2.67M, and earnings per share declined from -$0.2581 to -$0.2609.
D
Sell
5/5/2022Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, efficiency index and volatility index. Total capital declined 13.08% from $14.28M to $12.41M.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, efficiency index and volatility index. Total capital declined 13.08% from $14.28M to $12.41M.
D
Sell
3/2/2022Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E on 3/2/2022 due to an increase in the volatility index and valuation index.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to D- from E on 3/2/2022 due to an increase in the volatility index and valuation index.
E
Sell
12/1/2021Upgraded
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to E from E- on 12/1/2021 due to an increase in the growth index and total return index. Earnings per share increased from -$0.5746 to -$0.46.
Acurx Pharmaceuticals, Inc. (ACXP) was upgraded to E from E- on 12/1/2021 due to an increase in the growth index and total return index. Earnings per share increased from -$0.5746 to -$0.46.
E
Sell
9/20/2021None
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E- from U on 09/20/2021.
Acurx Pharmaceuticals, Inc. (ACXP) was downgraded to E- from U on 09/20/2021.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
